Noxopharm Limited (ASX:NOX)
Australia · Delayed Price · Currency is AUD 0.0770
0.00 (0.00%)
Jan 30, 2026, 3:58 PM AEST
Noxopharm Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2016 - 2020 |
Other Revenue | 2.82 | 2.4 | 6.01 | 5.43 | 5.61 | Upgrade |
| 2.82 | 2.4 | 6.01 | 5.43 | 5.61 | Upgrade | |
Revenue Growth (YoY) | 17.52% | -60.06% | 10.71% | -3.20% | -32.29% | Upgrade |
Cost of Revenue | 4.27 | 2.94 | 10.65 | 7.78 | 12.56 | Upgrade |
Gross Profit | -1.45 | -0.53 | -4.64 | -2.35 | -6.95 | Upgrade |
Selling, General & Admin | 3.94 | 4.07 | 5.85 | 7.17 | 7.38 | Upgrade |
Operating Expenses | 3.94 | 4.07 | 6.01 | 7.43 | 7.64 | Upgrade |
Operating Income | -5.39 | -4.6 | -10.64 | -9.78 | -14.59 | Upgrade |
Interest Expense | -0.5 | -0.03 | -0.04 | -0.08 | -2.2 | Upgrade |
Interest & Investment Income | 0.01 | 0.01 | 0.08 | 0.05 | 0.14 | Upgrade |
Earnings From Equity Investments | - | - | - | - | -1.04 | Upgrade |
Other Non Operating Income (Expenses) | 0.53 | - | - | - | -0.43 | Upgrade |
EBT Excluding Unusual Items | -5.35 | -4.63 | -10.6 | -9.81 | -18.12 | Upgrade |
Gain (Loss) on Sale of Investments | 0.47 | 1.05 | -4.45 | -8.86 | 8.77 | Upgrade |
Pretax Income | -4.88 | -3.58 | -15.06 | -18.67 | -9.35 | Upgrade |
Earnings From Continuing Operations | -4.88 | -3.58 | -15.06 | -18.67 | -9.35 | Upgrade |
Net Income | -4.88 | -3.58 | -15.06 | -18.67 | -9.35 | Upgrade |
Net Income to Common | -4.88 | -3.58 | -15.06 | -18.67 | -9.35 | Upgrade |
Shares Outstanding (Basic) | 292 | 292 | 292 | 291 | 264 | Upgrade |
Shares Outstanding (Diluted) | 292 | 292 | 292 | 291 | 264 | Upgrade |
Shares Change (YoY) | - | - | 0.35% | 10.37% | 90.70% | Upgrade |
EPS (Basic) | -0.02 | -0.01 | -0.05 | -0.06 | -0.04 | Upgrade |
EPS (Diluted) | -0.02 | -0.01 | -0.05 | -0.06 | -0.04 | Upgrade |
Free Cash Flow | -5.82 | -0.68 | -10.95 | -13.73 | -8.85 | Upgrade |
Free Cash Flow Per Share | -0.02 | -0.00 | -0.04 | -0.05 | -0.03 | Upgrade |
Gross Margin | -51.25% | -22.28% | -77.14% | -43.27% | -123.97% | Upgrade |
Operating Margin | -190.96% | -191.71% | -177.12% | -180.14% | -260.21% | Upgrade |
Profit Margin | -173.15% | -149.07% | -250.52% | -343.86% | -166.66% | Upgrade |
Free Cash Flow Margin | -206.48% | -28.51% | -182.13% | -252.98% | -157.81% | Upgrade |
EBITDA | -5.38 | -4.6 | -10.49 | -9.52 | -14.33 | Upgrade |
EBITDA Margin | -190.89% | -191.64% | -174.55% | -175.32% | -255.55% | Upgrade |
D&A For EBITDA | 0 | 0 | 0.15 | 0.26 | 0.26 | Upgrade |
EBIT | -5.39 | -4.6 | -10.64 | -9.78 | -14.59 | Upgrade |
EBIT Margin | -190.96% | -191.71% | -177.12% | -180.14% | -260.21% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.